High-risk Coronary Patients Not Receiving Treatment

by VR Sreeraman on August 6, 2007 at 1:37 PM
High-risk Coronary Patients Not Receiving Treatment

Patients presenting to hospital with acute coronary syndrome (ACS) who are at high risk of death or recurrent coronary events are less likely to receive treatment than those at low or moderate risk, according to a study published in the latest Medical Journal of Australia.

Associate Professor Ian Scott, Director of Internal Medicine at Princess Alexandra Hospital in Brisbane, and his colleagues, say the most common reasons patients did not receive treatment included older age and a previous history of ACS.


Approximately 100,000 Australians are hospitalised each year with ACS.

Assoc Prof Scott says six out of eight therapies were used less frequently in high-risk than in low-risk patients.

"Patients at highest absolute risk of death or recurrent coronary events would be expected to derive greater benefit from treatment than lower-risk patients," says Assoc Prof Scott.

The study suggests treatment may be withheld for a number of reasons, including concerns over treatment related risk to the patient, underestimation of treatment benefits, cost-effectiveness, and lack of access to therapies.

Assoc Prof Scott's article says further research is needed to know which treatment omissions are responsible for the majority of poor outcomes.

In addition, he recommends professional education programs, tools to help physicians calculate individual patient risk, more specific guideline recommendations, and better networking between hospitals to equalise access to all available therapies.

The Medical Journal of Australia is a publication of the Australian Medical Association.

Source: AMA
Font : A-A+



Latest Research News

South Korea's 2050 Forecast: Negative Growth Amid Low Fertility
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
New Immunotherapy for Psoriasis & Vitiligo
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
2050 Forecast: 1.06 Billion Individuals to Face 'Other' Musculoskeletal Disorders
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Gene Therapies Can Disrupt Gaucher Disease Drug Market
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
NASH Cases Expected to Hit 26.55 Million in 7MM by 2032
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

High-risk Coronary Patients Not Receiving Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests